197 related articles for article (PubMed ID: 1394340)
1. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.
Rasmussen RA; Counts SL; Lambert JM; Collinson AR
Cancer Immunol Immunother; 1992; 35(5):355-63. PubMed ID: 1394340
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
3. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the selection of ricin A-chain anti-T immunotoxins for mature T cell depletion.
Derocq JM; Laurent G; Casellas P; Vidal H; Poncelet P; Fauser A; Demur C; Jansen F
Transplantation; 1987 Dec; 44(6):763-9. PubMed ID: 3501187
[TBL] [Abstract][Full Text] [Related]
6. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26.
Duke-Cohan JS; Morimoto C; Schlossman SF
Blood; 1993 Oct; 82(7):2224-34. PubMed ID: 8104537
[TBL] [Abstract][Full Text] [Related]
7. Selective T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins.
Izquierdo M; Balboa MA; Figuera A; López-Botet M
Clin Exp Immunol; 1988 Nov; 74(2):300-4. PubMed ID: 3265657
[TBL] [Abstract][Full Text] [Related]
8. [Preparation and study of cytotoxic properties of the immunotoxin anti-CD7/A-chain of ricin].
Tonevitskiĭ AG; Ershova GV; Agapov II; Toptygin AIu; Korotkova OV; Shereshkov SN; Kadagidze ZG; Baryshnikov AIu
Dokl Akad Nauk SSSR; 1991; 317(3):749-53. PubMed ID: 1720085
[No Abstract] [Full Text] [Related]
9. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of CD6- T cells from peripheral blood.
Rasmussen RA; Counts SL; Daley JF; Schlossman SF
J Immunol; 1994 Jan; 152(2):527-36. PubMed ID: 7904289
[TBL] [Abstract][Full Text] [Related]
12. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
15. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins.
May RD; Vitetta ES; Moldenhauer G; Dörken B
Cancer Drug Deliv; 1986; 3(4):261-72. PubMed ID: 2436739
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
17. Selective killing of tumor cells in vitro by an immunotoxin composed of ricin and monoclonal antibody against Ia antigen.
Wu M; Tang SL; Zang RJ; Yu H
Int J Immunopharmacol; 1990; 12(2):235-9. PubMed ID: 2329015
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ricin A-chain immunotoxins directed against human T cells.
Press OW; Vitetta ES; Farr AG; Hansen JA; Martin PJ
Cell Immunol; 1986 Oct; 102(1):10-20. PubMed ID: 3100054
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B
J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971
[TBL] [Abstract][Full Text] [Related]
20. Cell-type-specific cytotoxicity of anti-CD4 and anti-CD8 ricin immunotoxins against human alloreactive T-cell clones.
Uckun FM; Myers DE; Ledbetter JA; Wee SL; Vallera DA
Blood; 1989 Nov; 74(7):2445-54. PubMed ID: 2572287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
